Research Alliance Corporation III’s Oak Hill Bio combination is expected to close in the fourth quarter of 2026, supported by $55,000,000 of PIPE financing. Disclosure controls were ineffective as of September 30, 2026 due to a material weakness.
RACC · Research Alliance Corp III
Substantial doubt about the company's ability to continue as a going concern.
“This condition raises substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed Nov 16, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
The closing range uses available history since May 20, 2026; less than a full year is stored.
Latest documents
Research Alliance Corporation III seeks shareholder approval at its November 24, 2026 meeting for a business combination with Oak Hill Bio, which has a $160,000,000 base equity value, plus a $55,000,000 PIPE financing.
Research Alliance Corporation III agreed to acquire OHB Pediatrics Ltd., issue 16,000,000 shares to its shareholders, and raise $55,000,000 through a PIPE financing; the combined company will move to Delaware and become Oak Hill Bio Inc.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Shell Companies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RACC
this stock
Research Alliance Corp III
|
$91.62M | — | — | — | 0.1% |
|
VYLR
Vylor Inc.
|
$46.59B | — | — | — | 2.1% |
|
CLUS
Cluster Group Holdings Ltd Co
|
$8.00B | — | — | — | — |
|
DMII
Drugs Made In America Acquisition II Corp.
|
$651.65M | +3.3% | — | — | 0.2% |
|
EVAC
EQV Ventures Acquisition Corp. II
|
$606.10M | +3.4% | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 78.7%
- Net QoQ
- -267.4K sh
- Top holder
- Nantahala Capital Managem…
- Filed
- Nov 16, 2026
- This year
- 12
Research Alliance Corporation III’s Oak Hill Bio combination is expected to close in the fourth quarter of 2026, supported by $55,000,000 of PIPE financing. Disclosure controls were ineffective as of September 30, 2026 due to a material weakness.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RACC | -0.8% | -1.0% | — | -0.8% | — |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | +3.1% | +4.6% | — | +2.6% | — |